A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Tocilizumab

Sponsor

NYU Langone Health